Skip to main content

Table 1 Patient baseline characteristics

From: Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study

N (%) Total Never smoker 0< PYa ≤10 10<PYa ≤30 > 30a PY p-value
142 91(64.1) 12(8.5) 22(15.5) 17(11.9)
Age 65(54.5–75.7)      
  < 60 years 49(34.5) 33(36.3) 3(25) 8(36.4) 5(29.4) 0.842
  ≥ 60 years 94(65.5) 58(63.7) 9(75) 14(63.6) 12(70.6)
Sex
 male 50(35.2) 10(11) 8(66.7) 18(81.8) 14(82.4) 0.001
 Female 92(64.8) 81(89) 4(33.3) 4(18.2) 3(17.6)
ECOG
 0–1 123(86.6) 81(89) 11(91.7) 19(86.4) 12(70.6) 0.23
  ≥ 2 19(13.4) 10(11) 1(8.3) 3(13.6) 5(29.4)
Stageb
 recurrent 15(10.5) 12(13.2) 19(8.3) 1(4.5) 1(5.9) 0.33
 IIIA 7(4.9) 5(5.5) 1(8.3) 1(4.5) 0(0)
 IIIB 12(8.5) 8 (8.8) 0(0) 0(0) 4(23.5)
 IV 108(76.1) 66(72.5) 10(83.3) 20(90.9) 12(70.6)
  M1a 40(37) 24(36.4) 3(30) 7(35) 6(50.0) 0.77
  M1b 68(63) 42(63.6) 7(70) 13(65) 6(50.0)
Time of EGFR-TKI treatment
 First line 84(59.2) 60(65.9) 6(50) 11(50) 7(41.2) 0.16
 Second or higher line 58(40.8) 31(34.1) 6(50) 11(50) 10(58.8)
EGFR mutation
 19 del 91(64.1) 59(64.8) 10(83.3) 13(59.1) 9(52.9) 0.38
 21 L858R 51(35.9) 32(35.2) 2(16.7) 9(40.9) 8(47.1)
Type of EGFR TKI
 Gefitinib 107(75.4) 71(78) 6(50.0) 17(77.3) 13(76.5) 0.53
 Erlotinib 17(12) 9(9.9) 2(16.7) 3(13.6) 3(17.6)
 Afatinib 14(9.9) 9(9.9) 3(21.4) 1(4.5) 1(5.9)
 Osimertinib 4(2.7) 2(2.2) 1(8.3) 1(4.5) 0(0.0)
Brain metastasis
 Yes 42(29.6) 26(28.6) 5(41.1) 9(40.9) 2(11.8) 0.19
  1. Abbreviation: PY pack-years, ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor
  2. aOf the 51 ever-smokers, 28 were ex-smokers, and 23 were current smokers
  3. bClinical stage at the time of initial diagnosis was determined according to the American Joint Committee on Cancer (7th edition)
\